Sclerostin: therapeutic horizons based upon its actions

Area of Science:

• Genetics and Bone Biology
• Molecular Endocrinology

Background:

• The SOST gene encodes sclerostin, a key inhibitor of the Wnt signaling pathway.
• Loss-of-function mutations in SOST cause sclerosteosis and van Buchem's disease, characterized by high bone mass and density.
• Sclerostin's role in regulating bone metabolism is crucial for understanding skeletal diseases.

Purpose of the Study:

• To review the role of SOST gene mutations and sclerostin in bone mass regulation.
• To explore the therapeutic potential of targeting sclerostin for osteoanabolic therapies.

Main Methods:

• Review of clinical phenotypes (sclerosteosis, van Buchem's disease) linked to SOST gene mutations.
• Analysis of the Wnt pathway's regulation by sclerostin.
• Examination of preclinical and clinical data on anti-sclerostin antibodies.

Main Results:

• Inactivating SOST mutations lead to reduced sclerostin, Wnt pathway activation, and high bone mass.
• Individuals with SOST mutations exhibit increased skeletal strength and resistance to fractures.
• Anti-sclerostin antibodies effectively increase bone mass in animal models and human subjects.

Conclusions:

• Sclerostin is a critical regulator of bone mass, and its inhibition is osteoanabolic.
• Targeting sclerostin with antibodies represents a promising therapeutic strategy for osteoporosis and related bone conditions.